Literature DB >> 11378160

Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT.

A Dekeyne1, J M Rivet, A Gobert, M J Millan.   

Abstract

Rats were trained to recognize a discriminative stimulus (DS) elicited by the dopamine D(2)/D(3) receptor agonist, PD128,907 (0.16 mg/kg, i.p.), which suppressed frontocortical release of dopamine (DA) but not 5-HT. The selective 5-HT1A receptor agonists, 8-OH-DPAT and flesinoxan, dose-dependently generalized to PD128,907 with effective dose(50)s (ED50s) of 0.08 and 1.5mg/kg, s.c., respectively, and inhibited the release and synthesis of 5-HT but not of DA. The 'atypical' antipsychotic, clozapine, which displays weak partial agonist properties at 5-HT1A receptors, dose-dependently, though partially, generalized to PD128,907 (50%, 2.5mg/kg, s.c.). Further, S16924 and ziprasidone, which in a like manner, display partial agonist activity at 5-HT1A receptors, generalized with ED50s of 0.6 and 2.3mg/kg, s.c., respectively. In contrast, haloperidol, which is devoid of affinity at 5-HT1A sites, was inactive. At doses equivalent to those generalizing to PD128,907, clozapine, S16924 and ziprasidone reduced serotonergic (but not dopaminergic) transmission, whereas haloperidol was inactive. In rats trained to recognize a further D2/D3 agonist, 7-OH-DPAT (0.16 mg/kg, i.p.), generalization was obtained similarly with 8-OH-DPAT (ED50 = 0.07 mg/kg, s.c.), flesinoxan (3.4) and clozapine (0.6), but not with haloperidol. In conclusion, although PD128,907 and 7-OH-DPAT do not directly interact with 5-HT1A receptors or influence serotonergic transmission, their DS properties are mimicked by 5-HT1A receptor agonists at doses activating 5-HT1A but not D2/D3 (auto)receptors. These observations likely account for generalization of clozapine, S16924 and ziprasidone to PD128,907 and 7-OH-DPAT inasmuch as they behave as antagonists at D2/D3 receptors, yet agonists at 5-HT1A (auto)receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11378160     DOI: 10.1016/s0028-3908(01)00022-3

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  8 in total

1.  Quantitative analysis of the effects of some "atypical" and "conventional" antipsychotics on progressive ratio schedule performance.

Authors:  Z Zhang; J F Rickard; K Asgari; S Body; C M Bradshaw; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  2004-11-25       Impact factor: 4.530

2.  Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.

Authors:  Mark J Millan; Loretta Iob; Jean-Louis Péglion; Anne Dekeyne
Journal:  Psychopharmacology (Berl)       Date:  2006-09-19       Impact factor: 4.530

Review 3.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

Review 4.  Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders.

Authors:  Marc Fakhoury
Journal:  Mol Neurobiol       Date:  2015-04-01       Impact factor: 5.590

5.  Comparison of the effects of clozapine and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on progressive ratio schedule performance: evidence against the involvement of 5-HT1A receptors in the behavioural effects of clozapine.

Authors:  Z Zhang; J F Rickard; S Body; K Asgari; C M Bradshaw; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

6.  Effects of 8-OH-DPAT and WAY-100635 on performance on a time-constrained progressive-ratio schedule.

Authors:  M-Y Ho; S Body; S Kheramin; C M Bradshaw; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  2003-03-25       Impact factor: 4.530

7.  Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies.

Authors:  Fabio Panariello; Vincenzo De Luca; Andrea de Bartolomeis
Journal:  Schizophr Res Treatment       Date:  2010-12-06

8.  Atypical Antipsychotic Drug Ziprasidone Protects against Rotenone-Induced Neurotoxicity: An In Vitro Study.

Authors:  Kazuki Terada; Ayumi Murata; Erina Toki; Shotaro Goto; Hirofumi Yamakawa; Shuichi Setoguchi; Daisuke Watase; Mitsuhisa Koga; Jiro Takata; Kazuhisa Matsunaga; Yoshiharu Karube
Journal:  Molecules       Date:  2020-09-14       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.